These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9697728)

  • 21. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.
    Hodder SL; Cherry JD; Mortimer EA; Ford AB; Gornbein J; Papp K
    Clin Infect Dis; 2000 Jul; 31(1):7-14. PubMed ID: 10913389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses.
    Mascart F; Verscheure V; Malfroot A; Hainaut M; Piérard D; Temerman S; Peltier A; Debrie AS; Levy J; Del Giudice G; Locht C
    J Immunol; 2003 Feb; 170(3):1504-9. PubMed ID: 12538714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
    Blom J; Heron I; Hendley JO
    APMIS; 1994 Sep; 102(9):681-9. PubMed ID: 7946271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
    Berstad AK; Oftung F; Korsvold GE; Haugen IL; Froholm LO; Holst J; Haneberg B
    Vaccine; 2000 May; 18(22):2323-30. PubMed ID: 10738087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
    Khelef N; Danve B; Quentin-Millet MJ; Guiso N
    Infect Immun; 1993 Feb; 61(2):486-90. PubMed ID: 8423077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.
    Ausiello CM; Lande R; Urbani F; la Sala A; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
    Infect Immun; 1999 Aug; 67(8):4064-71. PubMed ID: 10417175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice.
    Bakhshaei P; Kazemi MH; Golara M; Abdolmaleki S; Khosravi-Eghbal R; Khoshnoodi J; Judaki MA; Salimi V; Douraghi M; Jeddi-Tehrani M; Shokri F
    J Interferon Cytokine Res; 2018 Apr; 38(4):161-170. PubMed ID: 29638208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.
    Ryan EJ; Nilsson L; Kjellman N; Gothefors L; Mills KH
    Clin Exp Immunol; 2000 Aug; 121(2):193-200. PubMed ID: 10931131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
    Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
    Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P; Chubb AP; Cownley K; Charles IG
    Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo.
    Xing DK; Canthaboo C; Corbel MJ
    Vaccine; 2000 Apr; 18(20):2110-9. PubMed ID: 10715525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
    Hendrikx LH; Schure RM; Oztürk K; de Rond LG; de Greeff SC; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Sep; 29(40):6874-80. PubMed ID: 21803088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
    Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
    Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.
    Asokanathan C; Corbel M; Xing D
    Hum Vaccin Immunother; 2013 Feb; 9(2):325-31. PubMed ID: 23291942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.
    Canthaboo C; Xing D; Wei XQ; Corbel MJ
    Infect Immun; 2002 Feb; 70(2):679-84. PubMed ID: 11796599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.
    Scheller EV; Cotter PA
    Pathog Dis; 2015 Nov; 73(8):ftv079. PubMed ID: 26416077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human T-cell immunity against Bordetella pertussis analyzed at clonal level.
    Tagliabue A; De Magistris MT; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():253-7. PubMed ID: 2908527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
    Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
    Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.